Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18)cause approximately 70% of cervical cancers worldwide. A phase3 trial was conducted to evaluate a quadrivalent vaccine againstHPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the preventionof high-grade cervical lesions associated with HPV-16 and HPV-18.
Methods In this randomized, double-blind trial, we assigned12,167 women between the ages of 15 and 26 years to receivethree doses of either HPV-6/11/16/18 vaccine or placebo, administeredat day 1, month 2, and month 6. The primary analysis was performedfor a per-protocol susceptible population that included 5305women in the vaccine group and 5260 in the placebo group whohad no virologic evidence of infection with HPV-16 or HPV-18through 1 month after the third dose (month 7). The primarycomposite end point was cervical intraepithelial neoplasia grade2 or 3, adenocarcinoma in situ, or cervical cancer related toHPV-16 or HPV-18.
Results Subjects were followed for an average of 3 years afterreceiving the first dose of vaccine or placebo. Vaccine efficacyfor the prevention of the primary composite end point was 98%(95.89% confidence interval [CI], 86 to 100) in the per-protocolsusceptible population and 44% (95% CI, 26 to 58) in an intention-to-treatpopulation of all women who had undergone randomization (thosewith or without previous infection). The estimated vaccine efficacyagainst all high-grade cervical lesions, regardless of causalHPV type, in this intention-to-treat population was 17% (95%CI, 1 to 31).
Conclusions In young women who had not been previously infectedwith HPV-16 or HPV-18, those in the vaccine group had a significantlylower occurrence of high-grade cervical intraepithelial neoplasiarelated to HPV-16 or HPV-18 than did those in the placebo group.(ClinicalTrials.gov number, NCT00092534
[ClinicalTrials.gov]
.)
Source Information
Address reprint requests to Dr. Laura A. Koutsky at the Department of Epidemiology, University of Washington, Box 359933, Lake Union Place, Suite 300, 1914 N. 34th St., Seattle, WA 98103, or at kouts{at}u.washington.edu.
Human Papillomavirus Vaccine
Miller N. B., Raychaudhuri G., Toerner J. G., Suba E. J., Raab S. S., the Viet/American Cervical Cancer Prevention Project , Garland S. G., Koutsky L. A., Sawaya G. F., Smith-McCune K., Agosti J. M., Goldie S. J.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:1154-1156, Sep 13, 2007.
Correspondence
This article has been cited by other articles:
Chokshi, D. A, Kesselheim, A. S
(2008). Rethinking global access to vaccines. BMJ
336: 750-753
[Full Text]
Giuliano, A. R., Salmon, D.
(2008). The Case for a Gender-Neutral (Universal) Human Papillomavirus Vaccination Policy in the United States: Point. Cancer Epidemiol. Biomarkers Prev.
17: 805-808
[Full Text]
Lembo, D., Donalisio, M., Rusnati, M., Bugatti, A., Cornaglia, M., Cappello, P., Giovarelli, M., Oreste, P., Landolfo, S.
(2008). Sulfated K5 Escherichia coli Polysaccharide Derivatives as Wide-Range Inhibitors of Genital Types of Human Papillomavirus. Antimicrob. Agents Chemother.
52: 1374-1381
[Abstract][Full Text]
Hughes, D S, Powell, N, Fiander, A N
(2008). Will vaccination against human papillomavirus prevent eye disease? A review of the evidence. Br. J. Ophthalmol.
92: 460-465
[Abstract][Full Text]
Hendrix, S. L.
(2008). Assessing Human Papillomavirus Vaccine Efficacy and Safety. JAOA: Journal of the American Osteopathic Association
108: S8-S12
[Abstract][Full Text]
Goldhaber-Fiebert, J. D., Stout, N. K., Salomon, J. A., Kuntz, K. M., Goldie, S. J.
(2008). Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination. JNCI J Natl Cancer Inst
100: 308-320
[Abstract][Full Text]
Kenter, G. G., Welters, M. J.P., Valentijn, A.R. P.M., Lowik, M. J.G., Berends-van der Meer, D. M.A., Vloon, A. P.G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Offringa, R., van der Burg, S. H., Melief, C. J.M.
(2008). Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. Clin. Cancer Res.
14: 169-177
[Abstract][Full Text]
Howard, M., Lytwyn, A.
(2007). The HPV vaccine: An analysis of the FUTURE II study. cfp
53: 2157-2159
[Full Text]
Melnikow, J.
(2007). Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women for at least 3 years. Evid. Based Med.
12: 168-168
[Full Text]
Ohri, L. K
(2007). HPV Vaccine: Immersed in Controversy. The Annals of Pharmacotherapy
41: 1899-1902
[Abstract][Full Text]
Mayrand, M.-H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlee, F., Franco, E. L., the Canadian Cervical Cancer Screening Trial Study,
(2007). Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. NEJM
357: 1579-1588
[Abstract][Full Text]
(2007). Additional articles abstracted in ACP Journal Club. Evid. Based Med.
12: 158-158
[Full Text]
Roy, H. K., Khandekar, J. D.
(2007). Biomarkers for the Early Detection of Cancer: An Inflammatory Concept. Arch Intern Med
167: 1822-1824
[Full Text]
Miller, N. B., Raychaudhuri, G., Toerner, J. G., Suba, E. J., Raab, S. S., the Viet/American Cervical Cancer Prevention Proje, , Garland, S. G., Koutsky, L. A., Sawaya, G. F., Smith-McCune, K., Agosti, J. M., Goldie, S. J.
(2007). Human Papillomavirus Vaccine. NEJM
357: 1154-1156
[Full Text]
Dawar, M. MD MHSc, Deeks, S. MD MHSc, Dobson, S. MD
(2007). Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ
177: 456-461
[Full Text]
Ogilvie, G. MD MSc, Krajden, M. MD, Maginley, J. RN, Isaac-Renton, J. MD, Hislop, G. MDCM MSc, Elwood-Martin, R. MD, Sherlock, C. MB, Taylor, D. BSN, Rekart, M. MD
(2007). Feasibility of self-collection of specimens for human papillomavirus testing in hard-to-reach women. CMAJ
177: 480-483
[Abstract][Full Text]
Rambout, L. BScPhm, Hopkins, L. MD MSc, Hutton, B. MSc, Fergusson, D. PhD
(2007). Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ
177: 469-479
[Abstract][Full Text]
Brisson, M. PhD, Van de Velde, N. MSc, De Wals, P. MD PhD, Boily, M.-C. PhD
(2007). Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ
177: 464-468
[Abstract][Full Text]
Raffle, A. E
(2007). Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ
335: 375-377
[Full Text]
Franco, E. L
(2007). Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted. BMJ
335: 378-379
[Full Text]
Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T., Gonzalez, P., Dubin, G., Porras, C., Jimenez, S. E., Lowy, D. R., for the Costa Rican HPV Vaccine Trial Group,
(2007). Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial. JAMA
298: 743-753
[Abstract][Full Text]
Markowitz, L. E.
(2007). HPV Vaccines Prophylactic, Not Therapeutic. JAMA
298: 805-806
[Full Text]
Fimbres, A., Barton, L. L.
(2007). How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?. AAP Grand Rounds
18: 16-17
[Full Text]
Chan, J. K., Berek, J. S.
(2007). Impact of the Human Papilloma Vaccine on Cervical Cancer. JCO
25: 2975-2982
[Abstract][Full Text]
(2007). HPV Vaccination Update: An Important Hurdle. JWatch Women's Health
2007: 2-2
[Full Text]
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W.K., Ferris, D. G., Steben, M., Bryan, J., Taddeo, F. J., Railkar, R., Esser, M. T., Sings, H. L., Nelson, M., Boslego, J., Sattler, C., Barr, E., Koutsky, L. A., the Females United to Unilaterally Reduce Endo/Ect,
(2007). Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. NEJM
356: 1928-1943
[Abstract][Full Text]
Baden, L. R., Curfman, G. D., Morrissey, S., Drazen, J. M.
(2007). Human Papillomavirus Vaccine -- Opportunity and Challenge. NEJM
356: 1990-1991
[Full Text]
Sawaya, G. F., Smith-McCune, K.
(2007). HPV Vaccination -- More Answers, More Questions. NEJM
356: 1991-1993
[Full Text]
(2007). Efficacy and Safety of the Quadrivalent HPV Vaccine. JWatch Infect. Diseases
2007: 1-1
[Full Text]
(2007). The HPV Vaccine and Cervical Neoplasia: Not Just for Warts Anymore. Journal Watch Dermatology
2007: 3-3
[Full Text]
(2007). HPV Vaccination: Data at Last. JWatch General
2007: 1-1
[Full Text]
Previous
